Introduction
============

Antipsychotic drugs (APDs) may lead to side effects such as obesity, diabetes, dyslipidemia, and cardiovascular disease. This adverse effect cluster presents an obstacle in the treatment and management of patients with schizophrenia or bipolar disorder, and limits patient adherence to medication and consequently adversely impacts treatment outcomes.

To counter the antipsychotic-induced weight gain, various pharmacological add-ons were investigated. Taking antidiabetics or antiobesity drugs as an adjuvant treatment, including metformin, orlistat, sibutramine, and naltrexone, is a popular approach for weight management and has been widely studied ([@B9]; [@B25]; [@B36]; [@B29]; [@B54]; [@B55]; [@B3]; [@B47]; [@B57]; [@B67]; [@B23]). Most of the studies reported significant reductions in body weight. Gastrointestinal agents, especially antacids like nizatidine, were reported may stop but not reduce the weight gain ([@B7], [@B8]; [@B6]). Topiramate, a type of anticonvulsant, shows a negative association with body weight gain and has been found to control antipsychotic-induced weight gain for subjects with schizophrenia or bipolar disorder ([@B36]; [@B1]; [@B65]; [@B41]).

Until recently, no study has been published comparing various pharmacological add-ons on antipsychotic-induced weight gain, from both direct and indirect evidence. The current systematic review and network meta-analysis analyzes and provides an update on the clinical effectiveness and safety of these add-ons in comparison to placebo on body weight, body mass index (BMI) reductions and number of withdrawn due to adverse effects.

Materials and Methods {#s1}
=====================

Literature Search and Eligibility Criteria
------------------------------------------

A comprehensive literature search was performed on electronic databases: PubMed (1946-), Embase (1974-), Cochrane library (1992-), and OpenGrey (2000-) until 31 July 2018. The specific concepts used in the search strategy were "antipsychotic agents" and "weight." We conducted literature search using Medical Subject Headings (MeSH) or Emtree, and free text terms. There were no restrictions on language. The bibliography listed in review papers and included publications were also checked.

Two investigators (CjZ and QZ) independently screened for eligible studies based on pre-defined eligibility criteria. Randomized controlled trials (RCTs) that examined the pharmacological interventions of weight management for antipsychotics-induced obesity were included. To avoid imprecise estimations, only those add-ons with at least two RCTs studied were included. Non-randomized or observational studies, case reports, commentaries, and letters-to-editors were excluded.

Data Extraction and Quality Assessment
--------------------------------------

The following data were extracted from the included studies: (1) study characteristics (publication year and patient population); (2) baseline characteristics (mean age, number of males, follow-up time, and ongoing antipsychotic treatment); and (3) outcome events (weight change \[kg\], BMI change \[kg/m^2^\], and number of withdrawn due to adverse events).

The quality of each study was evaluated, using the Cochrane Collaboration Risk of Bias tool, by two independent investigators (CjZ and QZ). Six domains were assessed for each RCT, including random sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome assessment, incomplete outcome data, selective reporting, and other sources of bias. Each domain would be assigned a judgment of 'Low risk' of bias, 'High risk' of bias, or 'Unclear risk' of bias. Any disagreement in quality assessment was resolved by discussion and consensus.

Statistical Analysis
--------------------

A network geometry was constructed based on the included studies for each add-on treatment. Each node represented an add-on and its size was weighted by the number of subjects of each add-on. The connecting line between two nodes meant a direct comparison existed and its thickness was determined by the number of studies included.

Network meta-analysis, comparing the body weight change, BMI change, and number of patients withdrawn due to adverse events among different pharmacological add-ons, was performed using a multivariate meta-regression model with random-effects, adopting a frequentist approach ([@B26]; [@B62]). The model allows for the inclusion of potential covariates, and accounts for the correlations from multi-arm trials, and mean difference (MD) for weight and BMI change and risk ratio (RR) for number of withdrawn due to adverse events of each add-on treatment was estimated ([@B60]).

To rank the prognosis for all the add-ons, we used surface under the cumulative ranking (SUCRA) values ([@B50]). Rank probabilities of all the add-ons were first estimated under a Bayesian framework. A step function was then applied to summarize the cumulative ranking for estimating the SUCRA values of each add-on, ranging from 0 to 1. Thus, large SUCRA values indicated a better prognosis.

The node-splitting approach and inconsistency model were used to test the consistency assumption ([@B21]). The former method involved fitting a series of node-splitting models, with one model for each add-on pairing for which there was direct and indirect evidence ([@B22]). The latter method first fits an inconsistency model and then conduct a Wald test to check whether there is significant inconsistency among the included studies ([@B61]). Sensitivity analysis was conducted by (1) excluding studies with both "blinding of participants and personnel" and "blinding of outcome assessment" ranked as "Unclear" or "High risk," as the outcomes (i.e., measurement of weight and BMI) were likely to be biased due to these two key components, and (2) limiting the analysis on studies with less than 12 months' follow-up.

The network meta-analyses were implemented by Stata/MP 13 with network and network graphs package ([@B14]; [@B53]; [@B61]).

Results
=======

Study Characteristics and Network Geometry
------------------------------------------

From 614 potential studies identified from the initial search, 27 randomized controlled trials (*n* = 1,349 subjects) satisfied inclusion/exclusion criteria and were included in this meta-analysis (Figure [1](#F1){ref-type="fig"} and Table [1](#T1){ref-type="table"}; [@B34]; [@B45], [@B43], [@B44]; [@B24], [@B25]; [@B32]; [@B42]; [@B31]; [@B10], [@B11]; [@B36]; [@B5]; [@B68], [@B66]; [@B1]; [@B13]; [@B41]; [@B58]; [@B15]; [@B28]; [@B48]; [@B12]; [@B18]; [@B3]; [@B37]; [@B47]). The mean age was 31.9 years old and 48.6% (*n* = 655) were males. The follow-up period was relatively short, ranging from 6 to 26 weeks. Among the included studies, one study recruited patients with autism spectrum disorder (ASD), two for patients with bipolar disorder, 20 for patients with schizophrenia and schizophrenic conditions and four for patients with various psychosis. Efficacy results on Topiramate were reported in 4 studies, Metformin in 13 studies, Reboxetine in 3 studies, Ranitidine in 2 studies, and Sibutramine in 4 studies (Figure [1](#F1){ref-type="fig"}).

![PRISMA flowchart of study selection.](fphar-09-01393-g001){#F1}

###### 

Summary of study characteristics of included study.

  Study    Country         Main diseases   Sample size                       Mean age (SD)                    Ongoing treatment   Intervention and control       Follow-up (weeks)
  -------- --------------- --------------- --------------------------------- -------------------------------- ------------------- ------------------------------ -------------------
  [@B1]    Iran            Schizophrenia   I: 16 (9, 56%) C: 16 (11, 69%)    I: 37.5 (5.7) C: 38.1 (4.6)      Clo                 I: Topiramate C: Placebo       8
  [@B3]    Canada          ASD             I: 28 (21, 75%) C: 32 (24, 75%)   I: 12.9 (2.85) C: 12.7 (2.64)    Mixed               I: Metformin C: Placebo        16
  [@B5]    Iran            Schizophrenia   I: 16 (11, 69%) C: 16 (10, 63%)   I: 11.25 (2.46) C: 8.93 (4.28)   Ris                 I: Metformin C: Placebo        12
  [@B10]   Canada          Schizophrenia   I: 36 (23, 64%) C: 36 (19, 53%)   I: 43.8 (11.4) C: 44.5 (12.0)    Ola                 I: Metformin C: Placebo        12
  [@B11]   Canada          Schizophrenia   I: 13 (6, 46%) C: 15 (8, 53%)     I: 45.6 (8.0) C: 49.4 (12.3)     Ola                 I: Metformin C: Placebo        12
  [@B12]   Austria         Schizophrenia   I: 6 (, 0%) C: 5 (, 0%)           I: 19-65 C: 19-65                Mixed               I: Sibutramine C: Placebo      24
  [@B13]   Venezuela       Schizophrenia   I: 24 (, 0%) C: 30 (, 0%)         I: 39.6 (9.7) C: 38.3 (8.7)      Clo                 I: Metformin C: Placebo        14
  [@B15]   Taiwan          Schizophrenia   I: 28 (13, 46%) C: 27 (15, 56%)   I: 41.8 (7.2) C: 41.4 (10.2)     Clo                 I: Metformin C: Placebo        24
  [@B18]   Sri Lanka       Schizophrenia   I: 34 (6, 18%) C: 32 (8, 25%)     I: 33.5 (9.9) C: 35.3 (10.7)     Mixed               I: Metformin C: Placebo        26
  [@B24]   United States   Schizophrenia   I: 19 (12, 63%) C: 18 (11, 61%)   I: 43.2 (10.6) C: 40.7 (9.9)     Ola                 I: Sibutramine C: Placebo      12
  [@B25]   United States   Schizophrenia   I: 11 (8, 73%) C: 10 (8, 80%)     I: 41.0 (10.0) C: 39.0 (10.0)    Clo                 I: Sibutramine C: Placebo      12
  [@B28]   United States   Schizophrenia   I: 75 (52, 69%) C: 71 (49, 69%)   I: 41.4 (11.5) C: 45.0 (10.3)    Mixed               I: Metformin C: Placebo        16
  [@B31]   United States   BPD             I: 18 (9, 50%) C: 20 (12, 60%)    I: 12.9 (2.4) C: 13.3 (2.4)      Mixed               I: Metformin C: Placebo        16
  [@B32]   Korea           Schizophrenia   I: 17 (7, 41%) C: 20 (12, 60%)    I: 35.3 (9.75) C: 37.6 (7.98)    Mixed               I: Topiramate C: Placebo       12
  [@B34]   Spain           Mixed           I: 29 C: 28                       I: NA C: NA                      Ola                 I: Ranitidine C: Placebo       16
  [@B36]   United States   BPD             I: 18 (4, 22%) C: 28 (7, 25%)     I: 40.6 (13.9) C: 41.7 (11.8)    Mixed               I: Sibutramine C: Topiramate   24
  [@B37]   India           Schizophrenia   I: 25 (22, 88%) C: 25 (23, 92%)   I: 30.3 (7.4) C: 32.2 (8.3)      Ola                 I: Ranitidine C: Placebo       8
  [@B41]   India           Schizophrenia   I: 33 (22, 67%) C: 34 (22, 65%)   I: 31.2 (9.7) C: 31.0 (10.1)     Ola                 I: Topiramate C: Placebo       12
  [@B42]   Germany         Mixed           I: 25 (0, 0%) C: 18 (0, 0%)       I: 35.2 (8.2) C: 34.5 (9.2)      Ola                 I: Topiramate C: Placebo       10
  [@B43]   Israel          Schizophrenia   I: 31 (23, 74%) C: 28 (15, 54%)   I: 30.3 (8.5) C: 29.5 (7.2)      Ola                 I: Reboxetine C: Placebo       6
  [@B44]   Israel          Schizophrenia   I: 29 (23, 79%) C: 14 (12, 86%)   I: 33.2 (9.7) C: 31.0 (8.2)      Ola                 I: Reboxetine C: Placebo       6
  [@B45]   Israel          Schizophrenia   I: 10 (6, 60%) C: 10 (5, 50%)     I: 34.6 (13.0) C: 26.5 (6.7)     Ola                 I: Reboxetine C: Placebo       6
  [@B47]   United States   Mixed           I: 12 (7, 58%) C: 13 (5, 38%)     I: 33.5 (10.1) C: 39.08 (8.62)   Ola                 I: Metformin C: Placebo        24
  [@B48]   Iran            Schizophrenia   I: 25 (16, 64%) C: 27 (17, 63%)   I: 38.5 (11.2) C: 37.7 (11)      Ola                 I: Ranitidine C: Placebo       16
  [@B58]   China           Schizophrenia   I: 32 (15, 47%) C: 34 (19, 56%)   I: 26.8 (4.2) C: 25.6 (4.6)      Mixed               I: Metformin C: Placebo        12
  [@B66]   China           Schizophrenia   I: 42 (0, 0%) C: 42 (0, 0%)       I: 25.7 (4.8) C: 27.1 (4.2)      Mixed               I: Metformin C: Placebo        24
  [@B68]   China           Schizophrenia   I: 18 (10, 56%) C: 19 (10, 53%)   I: 25.4 (3.9) C: 24.8 (3.5)      Ola                 I: Metformin C: Placebo        12

Clo, clozapine; Ola, olanzapine; Ris, risperidone

.

The network geometry was constructed (Figure [2](#F2){ref-type="fig"}). Most of the studies demonstrated low to moderate risk of bias in the six domains assessed. However, due to missing information or inappropriate methods on randomization, four studies were ranked as "Unclear" or "High risk" in "Random sequence generation" (Supplementary Figure [S1](#SM1){ref-type="supplementary-material"}).

![Network geometry of included studies (top, weight change; below, withdrawn due to adverse event).](fphar-09-01393-g002){#F2}

Effectiveness on Body Weight Change
-----------------------------------

For outcome of body weight change, 27 studies were included in the analysis. All the add-ons, except Ranitidine, showed significant weight reductions compared to placebo. Topiramate showed the lowest mean difference (MD) -3.07 kg (95% CI: -5.57, -0.48), followed by Sibutramine MD = -2.97 kg (95% CI: -4.18, -1.77), Metformin MD = -2.50 kg (95% CI: -3.21, -1.80), and Reboxetine MD = -2.25 kg (95% CI: -3.54, -0.95) (Table [2](#T2){ref-type="table"}). Results from both the node-splitting method and inconsistency model showed no evidence on the violation of consistency assumption between direct and indirect comparisons. As shown in Supplementary Figure [S2](#SM2){ref-type="supplementary-material"}, the pooled estimates were quite similar between consistency model (red diamonds) and inconsistency model (green diamonds), indicating that inconsistency covariates did not yield a significantly better fitting. The *p*-value = 0.166 from the Wald test further confirmed that there is no evidence on the violation of consistency assumption.

###### 

Summary of results on body weight change and BMI change.

  ------------------------- ---------------------- ------------------------- ------------------------- ------------------------- -------------------------
  Metformin                 -0.61 (-1.51, 0.30)    -0.26 (-0.93, 0.40)       0.23 (-0.78, 1.25)        0.59 (-0.51, 1.69)        -1.01 (-1.32, -0.69)^∗^
  -2.40 (-4.44, -0.36)^∗^   Ranitidine             0.34 (-0.68, 1.37)        0.84 (-0.43, 2.11)        1.19 (-0.14, 2.53)        -0.40 (-1.25, 0.45)
  -0.26 (-1.70, 1.18)       2.14 (-0.17, 4.46)     Reboxetine                0.50 (-0.63, 1.62)        0.85 (-0.35, 2.06)        -0.74 (-1.33, -0.16)^∗^
  0.47 (-0.88, 1.83)        2.87 (0.61, 5.14)^∗^   0.73 (-1.02, 2.47)        Sibutramine               0.35 (-0.72, 1.42)        -1.24 (-2.21, -0.27)^∗^
  0.57 (-2.08, 3.22)        2.97 (-0.25, 6.19)     0.83 (-2.05, 3.70)        0.10 (-2.42, 2.62)        Topiramate                -1.59 (-2.65, -0.54)^∗^
  -2.50 (-3.21, -1.80)^∗^   -0.10 (-2.04, 1.83)    -2.25 (-3.54, -0.95)^∗^   -2.97 (-4.18, -1.77)^∗^   -3.07 (-5.67, -0.48)^∗^   Placebo
  ------------------------- ---------------------- ------------------------- ------------------------- ------------------------- -------------------------

Bottom left panel reported the pooled mean difference (MD) of body weight changes from network meta-analysis, and the name to the right of each MD was the reference add-on. Top right panel reported the pooled MD of BMI changes from network meta-analysis, and the name below each MD was the reference add-on;

∗

statistical significant with

p

-value \< 0.05

.

To confirm the rank of effectiveness on body weight reduction, SUCRA values were calculated, and the rank from highest to lowest was Sibutramine, Topiramate, Metformin, Reboxetine, Ranitidine, and placebo (Table [3](#T3){ref-type="table"}).

In the sensitivity analysis by excluding the eight studies, similar pooled estimates were obtained and the rank order remained the same. Further sensitivity analysis by excluding studies with less than 12 months' follow-up showed that metformin, sibutramine and topiramate were consistently significant with a reduction in body weight at -2.54 (95% CI: -3.29, -1.79), -2.98 (95% CI: -4.34, -1.62), and -2.95 (95% CI: -5.87, -0.03), respectively. Ranitidine did not show any significant reduction in body weight, which was consistent to the main result as well. However, Reboxetine was reported only in studies with less than 12 months' follow-up, we were unable to check its sensitivity results.

Effectiveness on BMI Change
---------------------------

For the BMI change outcome, 24 studies were included in the analysis. A similar pattern was seen for BMI change, where all add-ons except cardiac Ranitidine showed statistically significant BMI reductions comparing to placebo. In particular, anticonvulsant presented the highest reduction, reaching MD = -1.59 kg/m^2^ (95% CI: -2.65, -0.54) (Table [2](#T2){ref-type="table"}). SUCRA results showed a consistent order from the highest to lowest: Topiramate, Sibutramine, Metformin, Reboxetine, Ranitidine, and placebo (Table [3](#T3){ref-type="table"}).

Tolerance and Safety on Number of Withdrawn Due to Adverse Events
-----------------------------------------------------------------

To assess the tolerance and safety of add-on treatments, we estimated the pooled RR for all add-ons comparing to placebo. All the pooled RR had wide 95% CI due to a relatively low prevalence of patients withdrawn due to adverse events in each included study. Among them, Topiramate had the highest but statistically insignificant RR 1.88 (95% CI: 0.44, 7.94). Therefore, current evidence did not reveal a significantly higher safety issue by using add-ons in the short-term period follow-up.

###### 

Summary of results from SUCRA.

  Add-ons       Body weight reduction   BMI reduction   Withdrawn due to adverse event              
  ------------- ----------------------- --------------- -------------------------------- --- ------ ----
  Sibutramine   80.0                    1               72.7                             2   65.0   2
  Topiramate    77.2                    2               89.1                             1   28.8   5
  Metformin     64.2                    3               63.5                             3   34.5   4
  Reboxetine    56.8                    4               44.8                             4   66.3   1
  Ranitidine    12.4                    5               26.1                             5   NA     NA
  Placebo       9.2                     6               3.8                              6   65.0   2

Discussion
==========

Current published systematic reviews on add-ons controlling APD-induced weight gain were either focused on one particular medication (e.g., metformin) ([@B27]; [@B38]; [@B46]; [@B19]; [@B52]), or indirectly compared different medications in a qualitative way, i.e., ranking the treatment effects simply based on the pair-wise meta-analyses results ([@B38]; [@B35]; [@B17]; [@B30]; [@B39]; [@B16]; [@B63]; [@B69]). The current review aims to quantitatively synthesize the weight and BMI reduction effects through a combination of both direct and indirect evidence. A total of 27 studies were included, among which only one study reported head-to-head comparisons between any two of the add-ons ([@B36]). Hence, by using network meta-analysis we were able to allow indirect comparisons between the add-ons as well as against placebo.

Notably, although our results showed that Sibutramine ranked first in body weight reduction and second in BMI reduction, its license has been withdrawn in many countries due to its adverse effects. Hence, Sibutramine should not be adopted to treat antipsychotic-induced weight gain. Sibutramine is an antiobesity medication affecting both serotonin and norepinephrine reuptake ([@B25]). Although the tolerance in this current review is not significantly lower than placebo, the Sibutramine Cardiovascular Outcomes Trial confirmed that subjects with preexisting cardiovascular disease on long-term treatment with Sibutramine had a significantly increased risk for non-fatal myocardial infarction and non-fatal stroke but not cardiovascular death or all-cause mortality ([@B56]). Converging with previous studies, we strongly suggest that we should not adopt sibutramine to treat antipsychotic-induced weight gain.

Some longitudinal studies suggest using body composition data rather than only measurements of body weight for understanding the relationship with disability and mortality ([@B51]; [@B40]). Current systematic reviews included BMI changes as one of the efficacy outcomes as well. Topiramate showed the best performance on controlling BMI based on our meta-analysis. It is an anticonvulsant blocking α-amino-3-hydroxy-5-methylisoxazole-4-propionic (AMPA)/kainate-gated ion and sodium channels and positively modulate GABA receptors ([@B59]). The side effect of weight loss when using Topiramate has been documented and been applied to treatment for adiposity caused by eating disorders ([@B4]; [@B33]). In our current review, it showed excellent weight and BMI reduction. The adverse effects, reported in the included studies, were mild to moderate without serious adverse effects. Paresthesia was the most common side effect observed in most of the included studies ([@B32]; [@B1]; [@B41]).

Metformin, a major antidiabetic medication, was widely studied in the literature on controlling antipsychotic induced weight gain and was proven to be effective ([@B19]; [@B52]). Klein et al. reported its efficacy of reducing weight gain in children and adolescents who were treated with olanzapine as well ([@B31]). One of the reasons may be explained by its effects in enhancing the glycaemic control effects of insulin, antagonizing glucagon, and suppressing gluconeogenesis and glycogenolysis ([@B64]). Similar reduction in BMI was reported in a recent pair-wise meta-analysis at -0.89 (95% CI -1.20, -0.58) ([@B69]). Although the rank of antidiabetics were generally lower than Topiramate and Sibutramine, Metformin showed long-term tolerance and weight loss effect for type 2 diabetes patients, even over 10 years ([@B49]; [@B20]). This evidence highlights the potential long-term use of metformin for antipsychotic-induced weight gain patients as well.

Of note, apart from pharmacological add-ons, nutritional and behavioral interventions are important for weight control. A recent systematic review reported that non-pharmacological interventions, either individual or group interventions, or cognitive--behavioral therapy as well as nutritional counseling were effective in reducing or attenuating antipsychotic-induced weight gain compared with treatment as usual, with treatment effects maintained over follow-up ([@B2]). Our review did not consider including these interventions due to high heterogeneity from study to study, but the combination of both pharmacological and non-pharmacological interventions might be promising for further controlling the weight gain.

The current evidence in our study showed relatively good tolerance and safety of using these pharmacological add-ons. However, given that most of the included RCTs had relatively short period of follow-up, further evidence on potential long-term adverse effects are needed.

Study Limitations
-----------------

In total, only 6 out of 27 included RCTs followed up more than half a year. The relative short period of follow-up time limited the ability of our findings to be extrapolated to longer periods, as the adherence of medication, etc., may alter the effectiveness or the rank in the long run. Therefore, primary studies on the long-term effects of pharmacological add-ons are needed. As mentioned above, nutritional and behavioral intervention, which were not included in the review, are alternatives for controlling APD-induced weight gain. We would expect primary and secondary studies on evaluating the rank of effectiveness on both intervention, and additive benefits when combining both.

Conclusion
==========

Topiramate, and Metformin are effective add-on treatments in controlling antipsychotic-induced weight gain, comparing to placebo. They are well tolerated over a short-term period. More importantly, we propose to conduct a large sample long-term cohort study to explore the optimal treatment methods for treating antipsychotic-induced weight gain in long term.
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